$ 2.01
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Strong growth
About
INmune Bio, Inc., a clinical-stage immunotherapy company, focuses on developing drugs to reprogram the patient's innate immune system to treat disease. The company develops and commercializes product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. Its development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma and patients with...
Company Valuation
From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks.
Target Price
The average target price of INMB is 5.1 and suggests 154% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increa
